Keywords: lipobay, selected, large, uk, study, diabetics, bayer
Lipobay Selected For Large UK Study In Diabetics
Article | 24 June 1997
Bayer's HMG-CoA reductase inhibitor Lipobay (cerivastatin) has beenselected for inclusion in a large-scale UK study which will determine whether lipid-lowering ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
